Last updated: February 20, 2026
What is NDC 73070-0100?
NDC 73070-0100 corresponds to a specific drug product. Based on available data, it is identified as Erythropoietin Alfa (Epoetin Alfa) for injection. This biologic medication is used to treat anemia associated with chronic kidney disease, chemotherapy, and certain other conditions.
Market Overview
Market Size and Growth
The erythropoietin Alfa market has experienced steady growth. In 2022, the global erythropoietin market was valued at approximately USD 7.2 billion, expected to reach USD 9 billion by 2027, with a compound annual growth rate (CAGR) of 4-5%.[1]
Market Segments
- Formulation: Bulk vs. prefilled syringes
- Indications: Anemia in chronic kidney disease, chemotherapy, HIV
- End Users: Hospitals, clinics, specialty pharmacies
Key Competitors
Major players include:
| Company |
Product Name |
Market Share (approx.) |
Notes |
| Amgen |
Epogen, Procrit |
50% |
Pioneered recombinant erythropoietin development |
| Johnson & Johnson |
Darbepoetin alfa |
20% |
Longer-acting agent |
| Others |
Biosimilar offerings |
30% |
Entry of biosimilars increases market competition |
Regulatory Trends
- FDA Approvals: Biosimilars approved since 2017, increasing market options.
- Pricing pressures: Driven by biosimilar entry and policy efforts to reduce drug costs.
Price Analysis
Current Pricing Overview
| Product |
Average Wholesale Price (AWP) per unit |
Notes |
| Epogen (Amgen) |
USD 150 per 40,000 IU |
Brand premium pricing |
| Biosimilar (e.g., Retacrit) |
USD 100 per 40,000 IU |
30-40% discount vs. originator product |
Factors Influencing Price
- Manufacturing costs: Higher for biologics due to complex production
- Patent landscape: Patent expirations (e.g., Procrit expired in 2015) have led to biosimilar entry
- Market entry barriers: Regulatory approval for biosimilars varies globally, affecting pricing strategies
- Market demand: Increases with growth in target patient populations
Price Projections (Next 5 Years)
Assuming biosimilar adoption accelerates and manufacturers implement cost efficiencies:
| Year |
Estimated Average Price per 40,000 IU |
Rationale |
| 2023 |
USD 130 |
Existing biosvials entering, slight price compression |
| 2024 |
USD 120 |
Greater biosimilar availability, competitive pressure |
| 2025 |
USD 110 |
Further biosimilar proliferation, market normalization |
| 2026 |
USD 105 |
Increased manufacturing efficiencies |
| 2027 |
USD 100 |
Potential for further biosimilar competition, price stabilization |
Market Risks and Opportunities
Risks
- Biosimilar market entry barriers: Regulatory, patent litigation
- Pricing controls: Policies aimed at reducing biologic costs
- Evolving treatment standards: Alternative anemia treatments gaining traction
Opportunities
- Expansion into emerging markets: Growing healthcare infrastructure
- Biosimilar adoption: Significant market share potential
- New indications: Off-label uses or expanded EUA approvals
Key Takeaways
- The NDC 73070-0100 product, likely erythropoietin Alfa, operates in a market valued at USD 7.2 billion, projected to grow at 4-5% annually.
- Market leadership is held by Amgen, with biosimilars gaining market share since 2017.
- Prices for current biologic products hover around USD 150 per 40,000 IU, with biosimilars offering substantial discounts.
- Price projections suggest gradual reductions, approaching USD 100 by 2027, driven by biosimilar competition.
- Market risks include regulatory hurdles and policy-driven price controls, while opportunities lie in biosimilar adoption and expanding global access.
FAQs
1. How do biosimilars impact the pricing of erythropoietin products?
Biosimilars introduce price competition, typically reducing prices by 30-40% relative to originator biologics.
2. What factors influence biosimilar market entry timelines?
Regulatory approval processes, patent litigation, and manufacturing development can delay biosimilar entry.
3. Are there significant regional differences in pricing?
Yes. U.S. prices tend to be higher than in Europe or emerging markets, influenced by payer policies and patent protections.
4. What is the primary driver of demand for NDC 73070-0100?
The prevalence of anemia caused by chronic kidney disease and chemotherapy is the main demand driver.
5. How might policy changes affect future prices?
Increased pricing regulation or incentives for biosimilar use could further reduce prices, impacting profit margins.
References
[1] MarketsandMarkets. (2022). Erythropoietin Market by Application, End User, and Region. MarketsandMarkets Report.
